Abstract Number: 0790 • ACR Convergence 2022
Sustainability of Immunogenicity of BNT162b2 Vaccine in Patients with Autoimmune Rheumatic Disease, a Retrospective Comparative Study
Background/Purpose: The sustainability of the immunogenicity of BNT162b2 anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in patients with autoimmune rheumatic diseases (ARDs) receiving immunomodulators…Abstract Number: 0925 • ACR Convergence 2022
Impact of Initiating Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs on Pain Medication Use in Patients with Rheumatoid Arthritis
Background/Purpose: Chronic pain associated with rheumatoid arthritis (RA) leads to impaired patient function and quality of life. Prior studies suggest initiation of disease-modifying antirheumatic drugs…Abstract Number: 1208 • ACR Convergence 2022
Development and Validation of a Prognostic Model for Methotrexate Discontinuation with Abnormal Monitoring Blood-test Results: A Cohort Study Using Data from Clinical Practice Research Datalink Gold and Aurum
Background/Purpose: Patients established on long-term low-dose weekly methotrexate treatment undergo 3-monthly monitoring blood-tests to facilitate early detection of drug-related adverse events. Regular testing may not…Abstract Number: 1493 • ACR Convergence 2022
Impact of Delay of Treatment with Disease Modifying Antirheumatic Drugs (DMARDs) in Psoriatic Arthritis: Lessons from the CorEvitas PsA/SpA Registry
Background/Purpose: There is evidence that a delay between psoriatic arthritis (PsA) symptom onset and diagnosis contributes to worse outcomes, yet the impact of delayed DMARD…Abstract Number: 1954 • ACR Convergence 2022
Development of the Patient-Important Outcomes Data Repository (PIONEER) for Rheumatic Diseases; An Enhanced Database Combining Electronic Medical Data with Insight from Chart Reviews
Background/Purpose: Clinical and non-clinical forces contribute to real-world treatment effectiveness, yet most studies focus on efficacy in an idealized setting. To identify factors impacting clinical…Abstract Number: 2144 • ACR Convergence 2022
JAK Inhibition Re-balances Gene Expression Profile of Circulating Immune Cells in Patients with Psoriatic Arthritis
Background/Purpose: Janus Kinase (JAK)/Signal Transducers and Activator of Transcription (STAT) is not only involved in IL23- signaling, but rather implemented into a broad range of…Abstract Number: 0093 • ACR Convergence 2022
Comparison of Faculty and Fellow Prescribing Patterns for Rheumatoid Arthritis in an Urban, Academic Hospital
Background/Purpose: Timely initiation of DMARDs in rheumatoid arthritis (RA) is necessary to prevent significant morbidity and mortality. Yet, patients from marginalized groups are less likely…Abstract Number: 0295 • ACR Convergence 2022
Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic DMARDs: Results Through 5 Years from the SELECT-NEXT Study
Background/Purpose: In the phase 3 SELECT-NEXT study, upadacitinib (UPA) demonstrated efficacy at wk 12 and sustained efficacy up to wk 60 in patients with rheumatoid…Abstract Number: 0535 • ACR Convergence 2022
Increase Rates of Bacterial Infection in Patients with ‘Pre-RA’
Background/Purpose: In 'pre-RA' there is evidence of disordered immunity manifest by the presence of auto-antibodies, increased concentration of pro-inflammatory cytokines (e.g. TNF) and acute phase…Abstract Number: 0791 • ACR Convergence 2022
Immunogenicity and Safety of a Three-dose SARS-CoV-2 Vaccination Strategy in Patients with Immune-mediated Inflammatory Diseases on Immunosuppressive Therapy
Background/Purpose: Humoral vaccine responses to SARS-Cov-2 vaccines are impaired and short lasting in patients with immune-mediated inflammatory diseases (IMIDs). Concerns have been raised regarding their…Abstract Number: 0926 • ACR Convergence 2022
Methotrexate Polyglutamates Exposure – Response Modelling in a Large Cohort of Rheumatoid Arthritis Patients Starting Methotrexate
Background/Purpose: Optimal dosing of low-dose methotrexate (MTX) is a challenge in rheumatoid arthritis (RA) because of substantial interpatient variation of response and because no stable…Abstract Number: 1209 • ACR Convergence 2022
Impact of Change in Disease Modifying Antirheumatic Drug Therapy on Disease Activity Measures: Findings from a Large Contemporaneous Real-World Longitudinal Database of Psoriatic Arthritis Patients
Background/Purpose: While many clinical trials provide direct comparisons between biologic disease modifying antirheumatic drugs (bDMARD) and nonbiologic DMARDs (nDMARD), there is a need for to…Abstract Number: 1585 • ACR Convergence 2022
Decreased Discontinuation and Switching of B/tsDMARD Therapy in RA Patients When Treatment Is Aligned with a Molecular Signature Response Classifier: An Analysis from the Study to Accelerate Information of Molecular Signatures (AIMS)
Background/Purpose: Rheumatoid arthritis (RA) patients with inadequate response to methotrexate often experience trial-and-error treatment selection due to a lack of guidance from clinical guidelines or…Abstract Number: 1958 • ACR Convergence 2022
The Increased Risk of Staphylococcus Aureus Bacteremia in Rheumatoid Arthritis – What Is the Impact of Glucocorticoids, Biologic Disease-Modifying Anti-Rheumatic Drugs and Disease Activity: A Danish Nationwide Nested Case-Control Study in the DANBIO Registry
Background/Purpose: Staphylococcus aureus bacteremia (SAB) has high mortality.[1] We have previously identified an approximately doubled risk in patients with rheumatoid arthritis (RA),[2] but the role…Abstract Number: 2146 • ACR Convergence 2022
Efficacy of Upadacitinib in Patients with Psoriatic Arthritis and Prior Exposure to Anti-TNF Therapy in the SELECT-PsA 2 Trial Through 2 Years
Background/Purpose: Patients with psoriatic arthritis (PsA) who experience anti-TNF failure and switch to another TNF inhibitor as second- or third-line therapy typically show poorer responses…
- « Previous Page
- 1
- …
- 30
- 31
- 32
- 33
- 34
- …
- 48
- Next Page »